The $70 million verdict a Philadelphia jury levied against Janssen Pharmaceuticals on July 1 may not survive challenges that it is excessive, but the award was a definitive win for the plaintiffs in the Risperdal mass tort litigation, attorneys who work in the pharmaceutical arena said.

A Philadelphia jury July 1 returned the award against Janssen and in favor of a boy who claimed the antipsychotic drug, Risperdal, led to excess growth of breast tissue. The plaintiffs in A.Y. v. Janssen Pharmaceuticals had argued that the company knew the medication caused the condition, but failed to properly inform the medical community, emphasizing potential profits for the drug over its safety.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]